High-level tumour methylation of BRCA1 and RAD51C is required for homologous recombination deficiency in solid cancers
{{output}}
In ovarian and breast cancer, promoter methylation of BRCA1 or RAD51C is a promising biomarker for PARP inhibitor response, as high levels lead to homologous recombination deficiency (HRD). Yet the extent and role of such methylation in other cancers is not cl... ...
